Loss of Tight Junction Protein Promotes Development of Precancerous Cells
Jacqueline Mitchell (BIDMC Communications) (617) 667-7306, firstname.lastname@example.org
DECEMBER 12, 2018
BIDMC Research Briefs showcase groundbreaking scientific advances that are transforming medical care.Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer. Understanding how claudin 18 loss occurs and what pathways it regulates may provide new strategies to inhibit neoplastic progression in human gastric cancer patients.
In a first-of-its-kind investigation, researchers at Beth Israel Deaconess Medical Center analyzed gastric tissues from mice infected with the bacterium H pylori – which can cause stomach ulcers, gastritis and gastric cancer – as well as from mice genetically engineered to lack claudin 18. The team demonstrated that mice infected with the bacteria lost claudin 18 overtime compared to uninfected mice. The team further showed that the lack of claudin 18 alone was enough to prompt the development of precancerous, abnormal cells and polyps in the engineered mouse model. Their findings were published in the journal Gastroenterology.
“The results were very surprising,” said lead author Susan J. Hagen, PhD, an investigator at BIDMC and an Associate Professor of Surgery at Harvard Medical School. “Epithelial cells express numerous varieties of claudin proteins at the tight junction. We thought that other claudin molecules would compensate for the loss of claudin 18. It is incredible that manipulating only one protein in the stomach results in gastric cancer development.”
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.